{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:25:25Z","timestamp":1794939925073,"version":"4.9.1"},"reference-count":42,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2022,6,5]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Recent studies reported an association between non-alcoholic fatty liver disease (NAFLD) and increased risk of new-onset heart failure (HF). However, the magnitude of the risk and whether this risk changes with severity of liver disease remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of new-onset HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We systematically searched Scopus, Web of Science and PubMed from database inception to March 2022 to identify eligible observational studies, in which NAFLD was diagnosed by serum biomarkers\/scores, International Classification of Diseases (ICD) codes, imaging techniques or liver histology. The primary outcome was new-onset HF, as assessed mainly by ICD codes. Data from selected studies were extracted, and meta-analysis was performed using random-effects models to obtain summary hazard ratios (HRs) with 95% CIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 11 longitudinal cohort studies with aggregate data on 11\u2009242\u2009231 middle-aged individuals from different countries and 97\u2009716 cases of incident HF over a median of 10 years. NAFLD was associated with a moderately higher risk of new-onset HF (pooled random-effects hazard ratio 1.50, 95%\u2009CI 1.34 to 1.67, p&lt;0.0001;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =94.8%). This risk was independent of age, sex, ethnicity, adiposity measures, diabetes, hypertension and other common cardiovascular risk factors. Sensitivity analyses did not change these results. The funnel plot did not show any significant publication bias.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NAFLD is associated with a 1.5-fold higher long-term risk of new-onset HF, regardless of the presence of diabetes, hypertension and other common cardiovascular risk factors. However, the observational design of the studies does not allow for proving causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2022-327672","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T20:00:32Z","timestamp":1658779232000},"page":"372-380","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":125,"title":["Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals"],"prefix":"10.1136","volume":"72","author":[{"given":"Alessandro","family":"Mantovani","sequence":"first","affiliation":[{"name":"Endocrinology and Metabolism, Department of Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziana","family":"Petracca","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, Department of Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Csermely","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, Department of Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Beatrice","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, Department of Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonapace","sequence":"additional","affiliation":[{"name":"Division of Cardiology, IRCSS Sacro Cuore - Don Calabria Hospital, Negrar (VR), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rossi","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-2579","authenticated-orcid":false,"given":"Herbert","family":"Tilg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medizinische Universitat Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-7753","authenticated-orcid":false,"given":"Christopher D","family":"Byrne","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, Department of Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"2026062604350814000_72.2.372.1","doi-asserted-by":"publisher","DOI":"10.1053\/J.GASTRO.2020.01.052"},{"key":"2026062604350814000_72.2.372.2","unstructured":"MH L , Yeo YH , Li X , et al . Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019;2021."},{"key":"2026062604350814000_72.2.372.3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29466"},{"key":"2026062604350814000_72.2.372.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012"},{"key":"2026062604350814000_72.2.372.5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062604350814000_72.2.372.6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320622"},{"key":"2026062604350814000_72.2.372.7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026062604350814000_72.2.372.8","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"2021","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026062604350814000_72.2.372.9","doi-asserted-by":"crossref","unstructured":"Alon L , Corica B , Raparelli V . Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol 2021.","DOI":"10.1093\/eurjpc\/zwab212"},{"key":"2026062604350814000_72.2.372.10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.amjcard.2022.02.012","article-title":"Meta-Analysis of nonalcoholic fatty liver disease and incident heart failure","volume":"171","author":"Salah","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026062604350814000_72.2.372.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2026062604350814000_72.2.372.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"2026062604350814000_72.2.372.13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142"},{"key":"2026062604350814000_72.2.372.14","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2026062604350814000_72.2.372.15","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.207340"},{"key":"2026062604350814000_72.2.372.16","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.240457"},{"key":"2026062604350814000_72.2.372.17","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302972"},{"key":"2026062604350814000_72.2.372.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2016.10.024"},{"key":"2026062604350814000_72.2.372.19","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.14309\/ajg.0000000000000401","article-title":"Women with nonalcoholic fatty liver disease lose protection against cardiovascular disease: a longitudinal cohort study","volume":"114","author":"Allen","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2026062604350814000_72.2.372.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-020-01444-x","article-title":"Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea","volume":"20","author":"Roh","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"2026062604350814000_72.2.372.21","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic Dysfunction-Associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"2026062604350814000_72.2.372.22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021654","article-title":"Nonalcoholic fatty liver disease and risk of heart failure among Medicare beneficiaries","volume":"10","author":"Fudim","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026062604350814000_72.2.372.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-021-01374-8","article-title":"The association of hepatic steatosis and fibrosis with heart failure and mortality","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026062604350814000_72.2.372.24","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1007\/s10620-021-06954-y","article-title":"Fatty liver index and development of cardiovascular disease: findings from the UK Biobank","volume":"66","author":"Zou","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2026062604350814000_72.2.372.25","doi-asserted-by":"crossref","unstructured":"Simon TG , Roelstraete B , Hagstrom H , et al . Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 2021.","DOI":"10.1136\/gutjnl-2021-325724"},{"key":"2026062604350814000_72.2.372.26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/liv.12285","article-title":"Hepatic steatosis in diabetic patients does not predict adverse liver-related or cardiovascular outcomes","volume":"33","author":"Dunn","year":"2013","journal-title":"Liver Int"},{"key":"2026062604350814000_72.2.372.27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1148\/radiol.2019181793","article-title":"Association between nonalcoholic fatty liver disease at CT and coronary microvascular dysfunction at myocardial perfusion PET\/CT","volume":"291","author":"Vita","year":"2019","journal-title":"Radiology"},{"key":"2026062604350814000_72.2.372.28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014279","article-title":"Longitudinal association of Non\u2010Alcoholic fatty liver disease with changes in myocardial structure and function: the cardia study","volume":"9","author":"VanWagner","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026062604350814000_72.2.372.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-020-01192-4","article-title":"Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study","volume":"20","author":"Ichikawa","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026062604350814000_72.2.372.30","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/07853890.2021.1943514","article-title":"Association between the liver fat score (LFS) and cardiovascular diseases in the National health and nutrition examination survey 1999\u20132016","volume":"53","author":"Lee","year":"2021","journal-title":"Ann Med"},{"key":"2026062604350814000_72.2.372.31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.14309\/ajg.0000000000001606","article-title":"Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease","volume":"117","author":"Vieira Barbosa","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2026062604350814000_72.2.372.32","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0697"},{"key":"2026062604350814000_72.2.372.33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322572"},{"key":"2026062604350814000_72.2.372.34","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062604350814000_72.2.372.35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14044","article-title":"Association between non\u2010alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta\u2010analysis","volume":"39","author":"Mantovani","year":"2019","journal-title":"Liver Int"},{"key":"2026062604350814000_72.2.372.36","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"2026062604350814000_72.2.372.37","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324191"},{"key":"2026062604350814000_72.2.372.38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ehf2.13250","article-title":"Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT","volume":"8","author":"Peters","year":"2021","journal-title":"ESC Heart Failure"},{"key":"2026062604350814000_72.2.372.39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ehf2.12222","article-title":"Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction","volume":"5","author":"Yoshihisa","year":"2018","journal-title":"ESC Heart Failure"},{"key":"2026062604350814000_72.2.372.40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jacc.2021.11.007","article-title":"Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week","volume":"79","author":"Mantovani","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026062604350814000_72.2.372.41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062604350814000_72.2.372.42","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"The Lancet"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2022-327672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:17:00Z","timestamp":1782728220000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2022-327672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1,5]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/gutjnl-2022-327672"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2022-327672","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]}}}